The Novel C5aR Antagonist DF3016A Protects Neurons Against Ischemic Neuroinflammatory Injury
The central nervous system (CNS) constitutively expresses complement (C) membrane receptors and complement proteins, including the component C5a. This is a crucial terminal effector of the C cascade, mostly involved in pain and neuroinflammatory conditions. Aberrant activation of C5a protein and its receptor C5aR has been reported to play a critical role in neurodegenerative diseases, with important clinical consequences. Here we have investigated the effects of DF3016A, a novel selective C5aR antagonist, able to penetrate the blood-brain barrier (BBB), on cortical neurons exposed to oxygen-glucose deprivation-reoxygenation (OGD/R), a neuroinflammation-related process. We demonstrated that a mild ischemic insult induces an early upregulation of C5aR associated with the over-production of pro-inflammatory cytokines and the over-expression of the transcriptional regulatory factor miR-181. Furthermore, we report the first experimental evidence of the effect of DF3016A, modulating complement component C5a, on neurons in a model of injury. Interestingly, DF3016A protects neuronal viability by restoring intracellular calcium levels, thus opposing the increase in pro-inflammatory cytokine levels and miR-181 expression. Based on our results, we suggest that DF3016A is a novel C5aR antagonist promoting protective effects against OGD/R-induced damage that could be a new therapeutic approach to controlling CNS neuroinflammatory conditions.
KeywordsNeuroinflammation Complement C5a Cortical neurons Cytokines Pain
The authors are indebted to Professor Anthony Dickenson for the critical review of the final manuscript.
This work was supported by the Paolo Procacci Foundation (PPF) and Dompé Farmaceutici SpA funds.
Compliance with Ethical Standards
Conflicts of Interest
Laura Brandolini, Gianluca Bianchini, and Marcello Allegretti are employees of Dompé Farmaceutici SpA, Italy. The company has interests in the development of C5aR antagonists for the treatment of pain conditions. The other authors declare that they have no conflict of interest.
All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice where the studies were conducted.
- Alawieh A, Elvington A, Zhu H, Yu J, Kindy MS, Atkinson C, Tomlinson S (2015) Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement. J Neuroinflammation 12:247. https://doi.org/10.1186/s12974-015-0464-8 CrossRefGoogle Scholar
- Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, Cervellera MN, Di Cioccio V, Cesta MC, Galliera E, Martinez FO, Di Bitondo R, Troiani G, Sabbatini V, D'Anniballe G, Anacardio R, Cutrin JC, Cavalieri B, Mainiero F, Strippoli R, Villa P, Di Girolamo M, Martin F, Gentile M, Santoni A, Corda D, Poli G, Mantovani A, Ghezzi P, Colotta F (2004) Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A 101(32):11791–11796CrossRefGoogle Scholar
- Busch C, Girke G, Kohl B, Stoll C, Lemke M, Krasnici S, Ertel W, Silawal S, John T, Schulze-Tanzil G (2013) Complement gene expression is regulated by pro-inflammatory cytokines and the anaphylatoxin C3a in human tenocytes. Mol Immunol 53(4):363–373. https://doi.org/10.1016/j.molimm.2012.09.001 CrossRefGoogle Scholar
- Farkas I, Sárvári M, Aller M, Okada N, Okada H, Likó I, Liposits Z (2012) Estrogen receptor α and β differentially mediate C5aR agonist evoked Ca2+-influx in neurons through L-type voltage-gated Ca2+ channels. Neurochem Int 60(6):631–639. https://doi.org/10.1016/j.neuint.2012.02.024 CrossRefGoogle Scholar
- Gasque P, Singhrao SK, Neal JW, Götze O, Morgan BP (1997) Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol 150(1):31–41Google Scholar
- Hutchison ER, Kawamoto EM, Taub DD, Lal A, Abdelmohsen K, Zhang Y, Wood WH 3rd, Lehrmann E, Camandola S, Becker KG, Gorospe M, Mattson MP (2013) Evidence for miR-181 involvement in neuroinflammatory responses of astrocytes. Glia 61(7):1018–1028. https://doi.org/10.1002/glia.22483 CrossRefGoogle Scholar
- Leisengang S, Ott D, Murgott J, Gerstberger R, Rummel C, Roth J (2018 Dec 1) Primary cultures from rat dorsal root ganglia: responses of neurons and glial cells to somatosensory or inflammatory stimulation. Neuroscience. 394:1–13. https://doi.org/10.1016/j.neuroscience.2018.10.018 CrossRefGoogle Scholar
- Mascagni P, Sabbatini V, Biordi L, Martinotti S, Allegretti M, Marullo A, Caselli G, Bertini R (2000) R- and S-isomers of nonsteroidal anti-inflammatory drugs differentially regulate cytokine production. Eur Cytokine Netw 11(2):185–192Google Scholar
- Moriconi A, Cunha TM, Souza GR, Lopes AH, Cunha FQ, Carneiro VL, Pinto LG, Brandolini L, Aramini A, Bizzarri C, Bianchini G, Beccari AR, Fanton M, Bruno A, Costantino G, Bertini R, Galliera E, Locati M, Ferreira SH, Teixeira MM, Allegretti M (2014) Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief. Proc Natl Acad Sci U S A 111:16937–16942CrossRefGoogle Scholar
- Müller-Ladner U, Jones JL, Wetsel RA, Gay S, Raine CS, Barnum SR (1996) Enhanced expression of chemotactic receptors in multiple sclerosis lesions. J Neurol Sci 144(1–2):135–41Google Scholar
- Narayanan SV, Perez-Pinzon MA (2017) Ischemic preconditioning treatment of astrocytes transfers ischemic tolerance to neurons. Cond Med 1(1):2–8Google Scholar
- Paladini A, Fusco M, Coaccioli S, Skaper SD, Varrassi G (2015) Chronic pain in the elderly: the case for new therapeutic strategies. Pain Physician 18:E863–E876Google Scholar
- Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G (2016) Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician 19:11–24Google Scholar